SMMT

Market-moving news on Summit Therapeutics (NASDAQ: SMMT): filings, earnings, deals and other events, from REDFILED.

Ivonescimab is being studied as a first-line treatment for advanced non-small cell lung cancer.

SMMT

SUMMIT Partner Akeso Reports 8.2-Month Survival Edge Over Keytruda

Ivonescimab cut the risk of death 27% versus pembrolizumab in Akeso's Chinese Phase III HARMONi-2 trial, with median overall survival of 30.8 months.